register

News & Trends - MedTech & Diagnostics

Australian-first study for revolutionary technique to treat prostate cancer

Health Industry Hub | November 4, 2020 |

MedTech News: An Australian-first study has been launched to support the use of a revolutionary new technique to treat prostate cancer and reduce side-effects.

Many men suffer problems such as urinary incontinence and sexual dysfunction, along with the emotional distress both a cancer diagnosis and the impact of treatment can cause.

However, focal brachytherapy is a highly-targeted technique that focuses on the tumour rather than the whole prostate, delivering better outcomes for patients.

Australia’s largest cancer care provider, Icon, has teamed up with Victoria-based Epworth HealthCare to launch the LIBERATE clinical registry, which will monitor men who have had the treatment for low-to-intermediate risk prostate cancer.

It will span a five-year period to determine its effects on long-term quality of life and rates of cancer control for patients at Icon’s clinics in Epworth’s Richmond and Freemasons hospitals in Melbourne.

Epworth urologist Associate Professor Jeremy Grummet said the cutting-edge treatment was possible due to continued advances in diagnostic imaging technology.

“Now we can pinpoint the exact location of the tumour and directly administer radioactive seeds into it, further reducing the impact this treatment has on erectile, bladder and bowel function,” he said.

Unlike traditional brachytherapy developed over the past 40 years, this technique implants small radioactive seeds directly into the cancerous area of the prostate, destroying the diseased cells over a short period of time.

Icon Cancer Centre radiation oncologist Dr Andrew See said the minimally-invasive procedure, which requires a single day surgery, allows patients to quickly resume their lives.

“The brilliant thing is that the men walk out of the clinic a few hours later and return to normal life, but the effect continues for up to 100 days,” said Dr See, who has over 20 years’ experience in brachytherapy treatment for prostate cancer.

By building robust evidence for best practice, he said the LIBERATE project would help to ensure continued provision of treatments that benefit all patients.

“We hope this study will provide thousands of men living with an early prostate cancer diagnosis hope that they can maintain a good quality of life even through treatment,” Dr See added.


Human Resources

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Medtronic HR Director deep dives into shifting workplaces and leadership trends: International HR Day

Health Industry Hub | May 20, 2024 |

People & Culture: Coinciding with International HR Day, Karen Newell, Senior HR Director for ANZ at Medtronic, joined Health Industry […]

More


News & Trends - MedTech & Diagnostics

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Aussie medtech reveals new data on next-gen pulsed field ablation system for atrial fibrillation

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: An Australian-based medtech company announced promising results from the first-in-human study for its pulsed field ablation […]

More


News & Trends - MedTech & Diagnostics

Federal budget delivers 'mixed news' for radiologists

Federal budget delivers ‘mixed news’ for radiologists

Health Industry Hub | May 20, 2024 |

MedTech & Diagnostics News: The Royal College of Australian and New Zealand Radiologists (RANZCR) and the Interventional Radiology Society of […]

More


News & Trends - Pharmaceuticals

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

AstraZeneca, BMS and Noxopharm address findings of inquiry report into rare cancers

Health Industry Hub | May 20, 2024 |

Pharma News: The Senate Community Affairs References Committee has released its inquiry report into Equitable access to diagnosis and treatment […]

More


This content is copyright protected. Please subscribe to gain access.